SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-24-071452
Filing Date
2024-03-19
Accepted
2024-03-19 16:55:37
Documents
5
Effectiveness Date
2024-03-19

Document Format Files

Seq Description Document Type Size
1 S-8 d798719ds8.htm S-8 45951
2 EX-5.1 d798719dex51.htm EX-5.1 7612
3 EX-23.2 d798719dex232.htm EX-23.2 1433
4 EX-FILING FEES d798719dexfilingfees.htm EX-FILING FEES 22045
5 GRAPHIC g798719g0319052922192.jpg GRAPHIC 2408
  Complete submission text file 0001193125-24-071452.txt   81611
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-278070 | Film No.: 24764672
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)